120 studies found for:    bone marrow biopsy OR bone marrow aspiration OR bone marrow exam | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Conditions: Graft vs Leukemia;   Graft vs Host Disease
Intervention:
22 Recruiting Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
Conditions: Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
23 Not yet recruiting MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: MEK inhibitor MEK162;   Drug: idarubicin;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath  )
25 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)
26 Recruiting A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
27 Recruiting Use of G-CSF to Obtain Blood Cell Precursors
Conditions: Chronic Granulomatous Disease;   Healthy;   Immunologic Disease;   Leukocyte Adhesion Deficiency Syndrome;   Severe Combined Immunodeficiency
Intervention:
28 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath  );   Drug: Sirolimus (Rapamune  )
29 Recruiting Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Conditions: ALL;   B Cell Lymphoma;   Leukemia;   Large Cell Lymphoma;   Non-Hodgkin Lymphoma
Intervention: Biological: Anti-CD19- CAR
30 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
31 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
32 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
33 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
34 Recruiting Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Condition: Systemic Capillary Leak Syndrome
Intervention:
35 Recruiting EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Conditions: Lymphoma, AIDS-related;   Lymphoma, Large B-cell, Diffuse
Interventions: Biological: Rituximab;   Biological: filgrastim;   Drug: EPOCH
36 Recruiting A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers
Condition: Monoclonal B-Cell Lymphocytosis
Intervention:
37 Recruiting Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
38 Recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Conditions: Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
Intervention:
39 Recruiting Molecular and Clinical Studies of Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndrome
Intervention:
40 Recruiting Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Conditions: Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
Interventions: Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath  );   Drug: Sirolimus (Rapamune  );   Drug: Cyclophosphamide (Cytoxan  );   Procedure: Low Dose Irradiation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years